Annexon ANNX 深 滬
等待開盤 11-26 09:30:00 美东时间
4.44
-0.070
-1.55%
華盛通- 最 高4.60
- 今 開4.53
- 成交量 282.78万股
- 最 低 4.325
- 昨 收 4.51
- 總市值 6.62亿
- 52周最高 5.66
- 市盈率 靜 --
- 換手率 1.90%
- 52周最低 1.285
- 委 比 -99.43%
- 總股本 1.49亿
- 歷史最高 38.01
- 量 比 0.48
- 振 幅 6.10%
- 歷史最低 1.285
- 每 手 1
- 風險率 1.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Annexon stock rises after director purchases shares
Annexon (ANNX) stock rose after the company's director disclosed a purchase of shares for an approximate value of about $5M. The stock is up about 15% today. Muneer Satter, director at Annexon, bought...
11-21 01:02
美股牛股 | 社交电商平台WeShop单日暴涨500%！Adobe宣布19亿美元收购SEMrush
社交电商平台WeShop单日暴涨500%！SEMrush股价大涨74%，获Adobe19亿美元收购；碳酸锂价格突破10万元大关！锂矿公司SGML再涨33%>>
11-20 16:31
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
11-20 10:28
Wells Fargo Maintains Overweight on Annexon, Raises Price Target to $27
Wells Fargo analyst Derek Archila maintains Annexon (NASDAQ:ANNX) with a Overweight and raises the price target from $14 to $27.
11-20 03:12
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon, Inc. highlighted progress in its neuroinflammation platform, advancing therapies for Guillain-Barré Syndrome (GBS), geographic atrophy (GA) in dry AMD, and autoimmune diseases. Key milestones include the submission of the European Marketing Authorization Application (MAA) for tanr Pruittart in GBS by January 2026, potential first targeted therapy for GBS; topline results from the vonaprument Phase 3 trial in GA expected in late 2026; and...
11-10 21:05
纳斯达克生物科技指数收涨将近1.5%
成分股Applied Therapeutics收涨119.56%，Crinetics Pharma涨27.92%，Annexon涨20.79%表现第三。Kyv...
09-27 04:30
Annexon Biosciences to Participate in Upcoming September Investor Conferences
Annexon Biosciences (Nasdaq: ANNX) announced that CEO Douglas Love will participate in fireside chats at the Wells Fargo Healthcare Conference on September 3, 2025, and the Cantor Global Healthcare Conference on September 4, 2025. Live webcasts will be available on the company’s website, with replays archived for 30 days. Annexon is developing first-in-kind therapies targeting classical complement-driven neuroinflammation for neuroinflammatory di...
08-27 12:00
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
ANNEXON授予新员工60,000股购股权，行使价为每股2.44美元，分4年归属。该股权激励计划依据纳斯达克上市规则获得批准。ANNEXON专注于开发针对补体介导神经炎症疾病的创新疗法。
08-18 20:05
HC Wainwright & Co. Reiterates Buy on Annexon, Maintains $14 Price Target
HC Wainwright & Co. analyst Ananda Ghosh reiterates Annexon (NASDAQ:ANNX) with a Buy and maintains $14 price target.
08-15 21:06
Annexon Q2 EPS $(0.34) Beats $(0.37) Estimate
Annexon (NASDAQ:ANNX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.37) by 7.1 percent. This is a 47.83 percent decrease over losses of $(0.23) per share from the same
08-15 04:37
